Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8717449 | 0.88 | MAPT (0.46) | CA2CA9MAPTMEN1KMT2A | |
| SCHEMBL6697703 | 0.80 | ALDH1A1 (0.40) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL7508194 | 0.80 | MAPT (0.61) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL6701656 | 0.80 | ALDH1A1 (0.40) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL9174239 | 0.80 | MAPT (0.40) | CA2MAPTSMN1; SMN2CA1ALDH1A1 | |
| SCHEMBL3420454 | 0.80 | PTPRF (0.45) | CA2CA9MAPTMEN1KMT2A | |
| SCHEMBL6700261 | 0.78 | GHSR (0.42) | CA2CA9GHSRTGM2SMN1; SMN2 | |
| SCHEMBL1447189 | 0.77 | ALDH1A1 (0.39) | CA2CA9MAPTMEN1KMT2A | |
| SCHEMBL6993608 | 0.77 | MAPT (0.41) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL11703236 | 0.77 | HPGD (0.50) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1354882-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | DPP4, DPP3, DPP9 | CA2 467/4885CA9 192/4885MAPT 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.